Do 503B outsourcing facilities need FDA registration insurance?

FDA registration as a 503B outsourcing facility under FD&C Act section 503B triggers a regulatory exposure profile distinct from a 503A traditional compounding pharmacy. The 503B is subject to cGMP inspection on a routine cycle (typically every 2 years), to adverse event reporting under 503B(b)(5)(B), to drug supply chain security obligations, and to the same FDA enforcement tools available against pharmaceutical manufacturers.

No single "FDA registration insurance" product exists. The required coverage stack for a 503B is (1) products liability scaled to the toughest hospital purchase contract on file, typically $5 million to $10 million, (2) druggist professional liability for service-side errors at $2 million minimum, (3) dedicated recall coverage at $3 million to $5 million first-party, (4) cGMP-aligned property with validation extension, (5) cyber for HIPAA-scale PHI and hospital data flows, and (6) D&O for the operating entity, particularly when private equity ownership is involved.

The hospital purchase contracts that 503Bs supply are the practical insurance schedule driver - more than FDA registration itself. Hospitals enforce GPO supplier insurance schedules, AI/primary/non-contributory wording, 30-day notice, and recall coverage through procurement contract terms backed by stop-purchase clauses.